Navigation Links
Study demonstrates the anti-inflammatory properties of pine bark extract
Date:7/15/2009

(July 15, 2009) HOBOKEN, NJ A recent study published in International Immunopharmacology, reveals why Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, is effective for reducing inflammation and soothing pain associated with various health problems. Dr. Raffaella Canali of the National Research Institute on Food and Nutrition in Rome, Italy, found that Pycnogenol inhibits the generation of COX-2 and 5-LOX, two naturally occurring enzymes associated with a host of inflammatory conditions.

"This study reveals that Pycnogenol can actually decrease pain and reduce inflammatory conditions, as has been previously reported, by shutting down the production of specific enzymes involved with inflammation," said Dr. Canali.

Inflammation is a tightly controlled, concerted action of immune cells fighting infections, irritations and injuries. When inflammation goes out of control it may target the body's own tissue such as in arthritis or asthma. The worst known cases are the auto-immune diseases.

The study investigated healthy volunteers ranging from ages 35-50, who consumed Pycnogenol tablets (150 mg) for five consecutive days in the morning before breakfast. Blood was drawn before and after supplementation to investigate how immune cells respond towards pro-inflammatory stimuli. The behavior of specific white blood cells (leukocytes) for generating a repertoire of enzymes in inflammatory condition was tested by real-time PCR. The gene expression of enzymes COX-2, 5-LOX, FLAP and COX-1 were monitored and the products these enzymes generate, prostaglandins and leukotrienes, were quantified.

A baseline study revealed that the volunteers' immune cells rapidly initiated production of COX-2, 5-LOX and FLAP enzymes upon pro-inflammatory stimulation. Taking Pycnogenol almost entirely subdued COX-2, 5-LOX and FLAP induction in the immune cells of volunteers. Control studies showed that Pycnogenol did not have an effect on generation of the COX-1 enzyme, thus the potential for typical NSAID side effects is defied. While Pycnogenol is not a COX-2-specific inhibitor; it blocks the COX-2 enzyme production during inflammation only. There are COX-2 enzymes not involved in inflammation in other organs such as the kidneys, where it has important physiologic functions.

"Standard NSAID medications reduce the production of prostaglandins by COX enzymes for lowering the pain," explains Dr. Canali. "In contrast, Pycnogenol turns to the root of the problem, completely stopping the production of COX-2 in inflammation. Thus far, Pycnogenol seems to be a unique tool for modulating inflammatory processes."

These pharmacologic findings are consistent with past clinical trials of Pycnogenol that showed significantly lowered leukotriene levels in asthmatic patients, a condition originating from 5-LOX. Three recent clinical trials also showed pain relief and a reduced need for pain medication in arthritis patients after taking Pycnogenol, results that are linked to COX-2 inhibition. One arthritis study showed a significant reduction of inflammatory marker C-reactive protein. Pycnogenol has been shown to inhibit inflammation in several dysmenorrhoea studies and also a reduction in skin inflammation related to sunburn and acne.


'/>"/>

Contact: Megan Armand
marmand@mww.com
312-546-3506
MWW Group
Source:Eurekalert

Related medicine news :

1. American Hygiene Habits Getting Worse: International Study Reveals More Illness-Causing Germs Than Ever in American Kitchens
2. Study Demonstrates the Anti-Inflammatory Properties of Pine Bark Extract on Inflammatory Mediators COX-2 and 5-LOX
3. Study finds survival rates from gastrointestinal tumors improving among African-Americans
4. Mayo Clinic study continues to refine most effective methods to predict Alzheimers disease
5. Mayo Clinic Study Continues to Refine Most Effective Methods to Predict Alzheimers Disease
6. Reminder program dramatically increases mammography rates, Kaiser Permanente study finds
7. FAIR CEO Blasts Kaiser Foundation & Public Agenda HIV/AIDS Study Results as "Absolute Nonsense"
8. Reminder Program Dramatically Increases Mammography Rates, Kaiser Permanente Study Finds
9. Study estimates radiation dose, cancer risk from coronary artery calcium screening
10. Fluorescent probes may permit monitoring of chemotherapy effectiveness, Stanford study shows
11. Queens University study aims at early diagnosis for ADHD and Parkinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... A local study examining asthma ... 40 percent of participating fifth-grade students already have or are at risk for ... Research in the Division of Pulmonary, Allergy and Critical Care Medicine at ...
(Date:5/5/2016)... ... 2016 , ... Sun Health registered nurse Brittany Eads and ... Care Transitions program at the 9th Annual Orthopedic and Spine Summit held ... Post-Acute Environment Through Effective Transitions of Care.” , Major changes are taking place ...
(Date:5/5/2016)... ... (PRWEB) May 05, 2016 , ... Talent Tech Labs (TTL) ... the eve of National Nurses Week (May 6-12). Currently, HireNurses is a ... their enrollment into the Talent Tech Lab Virtual Incubation program, they will dramatically expand ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... The Lung Institute will celebrate ... attending a seminar at most clinic locations throughout the month of May. To date, the ... , “The rapid growth that we’ve seen is a testament to the success of this ...
(Date:5/5/2016)... ... May 05, 2016 , ... With May flowers, summer is just around the corner. Summer means ... respite from school and the ability to play all day and night. Parents often lament ... watch the little tykes themselves. Summer also means trips to the beach, backyard cookouts, fireworks ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016 Yissum Research Development ... today that it had signed an exclusive world-wide licensing ... of novel protein degradation and immunomodulatory drugs for cancer ... drug candidates representing first-in-class therapy for hematologic and solid ... The novel technology was developed by ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Myeloid Leukemia Market ... to their offering.       (Logo: ... Myeloid Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Myeloid Leukemia epidemiology, ...
(Date:5/3/2016)... , May 4, 2016 Research ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved significantly ... expected to be developed in coming years. Many cancer ... Cancer stem cell therapies are also expected to be ...
Breaking Medicine Technology: